Cargando…
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and sa...
Autores principales: | Yung, W K A, Albright, R E, Olson, J, Fredericks, R, Fink, K, Prados, M D, Brada, M, Spence, A, Hohl, R J, Shapiro, W, Glantz, M, Greenberg, H, Selker, R G, Vick, N A, Rampling, R, Friedman, H, Phillips, P, Bruner, J, Yue, N, Osoba, D, Zaknoen, S, Levin, V A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363506/ https://www.ncbi.nlm.nih.gov/pubmed/10944597 http://dx.doi.org/10.1054/bjoc.2000.1316 |
Ejemplares similares
-
Phase 1 study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas
por: Newlands, E S, et al.
Publicado: (2003) -
Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review
por: Hafazalla, Karim, et al.
Publicado: (2018) -
Clomiphene citrate reduces procarbazine-induced sterility in a rat model.
por: Weissenberg, R., et al.
Publicado: (1995) -
NICE verdict on Temozolomide: where next?
por: Brada, M
Publicado: (2002) -
Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)